TITLE

Pharma patents: India ranks second

PUB. DATE
September 2005
SOURCE
Siliconindia;Sep2005, Vol. 9 Issue 8, p15
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Reports on the increasing number of applications for patent of pharmaceutical products in India. Invention of critical life saving drugs by the pharmaceutical companies; Launch of drugs at a frenetic pace in Western countries; Attraction of international attention by the pharmaceutical firms which made them a potential acquisitions target.
ACCESSION #
18364420

 

Related Articles

  • Patents, Innovation and Access to New Pharmaceuticals. Grabowski, Henry // Journal of International Economic Law;Dec2002, Vol. 5 Issue 4, p849 

    This paper considers the role of intellectual property rights in the development of, and access to, new pharmaceuticals. A number of studies have found patents are significantly more important to pharmaceutical firms in appropriating the benefits from innovation compared with other high tech...

  • Changing Role of Intellectual Property. Hunt, Thomas // Drug Discovery & Development;Apr2004, Vol. 7 Issue 4, p13 

    Looks on changes in the role of intellectual property in the pharmaceutical industry in the United States. Pharmaceutical companies' patenting of the formulation for drugs; Drug discovery and development; Companies' adoption of more strategic and proactive approach to intellectual asset...

  • Reinventing an industry. Mandavilli, Apoorva // Nature;1/11/2007, Vol. 445 Issue 7124, p138 

    The article discusses the developments in Indian Pharmaceutical industry after India's compliance with Trade-Related Aspects of Intellectual Property Rights (TRIPS) in 2005. The efforts of several major Indian pharmaceutical companies to attune to the new patent regime are discussed. The...

  • Using intellectual property to map the organisational evolution of firms: Tracing a biotechnology company from startup to bureaucracy to a multidivisional firm. Daizadeh, Iraj // Journal of Commercial Biotechnology;Oct2006, Vol. 13 Issue 1, p28 

    The concomitant rise in the number of technology firms, US issued patents, and patent communications has forced researchers to investigate how such publicly known information can reveal characteristics and/or verify predictive models to describe the R&D-intensive firm. Here, we propose viewing...

  • Big interest in heavy drugs. Sanderson, Katharine // Nature;3/19/2009, Vol. 458 Issue 7236, p269 

    The article discusses how U.S. pharmaceutical companies are seeking profits through the modification of existing medications. Results from clinical trials have encouraged companies to buy the intellectual-property rights on many of the modified drugs, which have switched a hydrogen atom with a...

  • Destination: INDIA. Das, Rahul; Sharma, Anand K. // Drug Discovery & Development;Aug2007, Vol. 10 Issue 8, p35 

    The article focuses on India as an ideal venue for doing business related to drug discovery and development due to its patent considerations. It offered patent protection for pharmaceutical products and services including outsourcing and collaborations. Its outsourcing model entailed an alliance...

  • Reach-through claims for drug target patents: Rx for pharmaceutical policy. Bohrer, Robert A. // Nature Biotechnology;Jan2008, Vol. 26 Issue 1, p55 

    The article discusses the implications and relevance of new drug patent discoveries and validation in the advancement of pharmaceutical policies in the U.S. According to the author, the new discoveries and validation in medicine patent provides the biggest advantage in pharmaceutical research...

  • Stakeholder Views Regarding a Health Impact Fund (HIF), to Incentivise Pharmaceutical Innovation Relevant to Diseases of Poverty. Coles, D.; Ruto, E.; Frewer, L.J. // Global Health Governance;Summer2013, Vol. 6 Issue 2, p1 

    The HIF scheme, aims to create an alternative (Patent-2), to the existing Intellectual Property Rights (IPR) regime for rewarding pharmaceutical innovations through monopoly patents. Innovators would choose between the traditional IPR approach and the Patent-2 system to recoup innovation costs....

  • Whose Property Is It, Anyway?  // European Pharmaceutical Executive;May/Jun2006, p18 

    The article discusses the need for the pharmaceutical industry to change its attitude towards intellectual property to survive the changing climate of patent rights in Europe. It focuses on the issue of whether the possession of a single patent was sufficient grounds to bring someone else's...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics